This company has been marked as potentially delisted and may not be actively trading. Nuwellis (CHFS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CHFS vs. CUTR, VRAYQ, VIVE, ELMD, QTI, NRXS, ENSC, ARTL, APM, and MYNZShould you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Cutera (CUTR), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), QT Imaging (QTI), NeurAxis (NRXS), Ensysce Biosciences (ENSC), Artelo Biosciences (ARTL), Aptorum Group (APM), and Mainz Biomed (MYNZ). Nuwellis vs. Its Competitors Cutera ViewRay Viveve Medical Electromed QT Imaging NeurAxis Ensysce Biosciences Artelo Biosciences Aptorum Group Mainz Biomed Nuwellis (NASDAQ:CHFS) and Cutera (NASDAQ:CUTR) are both small-cap electromedical equipment industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Does the media refer more to CHFS or CUTR? In the previous week, Nuwellis' average media sentiment score of 0.00 equaled Cutera'saverage media sentiment score. Company Overall Sentiment Nuwellis Neutral Cutera Neutral Which has higher earnings and valuation, CHFS or CUTR? Nuwellis has higher earnings, but lower revenue than Cutera. Nuwellis is trading at a lower price-to-earnings ratio than Cutera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuwellis$5.51M8.66-$18.11M-$279.28-0.03Cutera$155.21M0.01-$162.83M-$6.58-0.01 Is CHFS or CUTR more profitable? Cutera has a net margin of -84.86% compared to Nuwellis' net margin of -254.26%. Cutera's return on equity of 0.00% beat Nuwellis' return on equity.Company Net Margins Return on Equity Return on Assets Nuwellis-254.26% -173.61% -131.01% Cutera -84.86%N/A -45.07% Do analysts recommend CHFS or CUTR? Cutera has a consensus price target of $3.00, suggesting a potential upside of 7,592.31%. Given Cutera's stronger consensus rating and higher possible upside, analysts plainly believe Cutera is more favorable than Nuwellis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cutera 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, CHFS or CUTR? Nuwellis has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Cutera has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CHFS or CUTR? 65.1% of Nuwellis shares are held by institutional investors. Comparatively, 90.7% of Cutera shares are held by institutional investors. 0.6% of Nuwellis shares are held by insiders. Comparatively, 0.4% of Cutera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCutera beats Nuwellis on 10 of the 14 factors compared between the two stocks. Get Nuwellis News Delivered to You Automatically Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHFS vs. The Competition Export to ExcelMetricNuwellisElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.69M$34.52M$5.55B$9.01BDividend YieldN/AN/A5.25%4.03%P/E Ratio-0.163.4728.0720.17Price / Sales8.66195.25432.62124.64Price / CashN/A41.3636.8257.86Price / Book0.622.198.125.62Net Income-$18.11M-$25.54M$3.16B$248.50M Nuwellis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHFSNuwellisN/A$7.90+11.1%N/A+76.9%$47.69M$5.51M-0.1666CUTRCuteraN/A$0.04-63.9%$3.00+7,592.3%-97.2%$787K$155.21M-0.01460Gap DownHigh Trading VolumeVRAYQViewRayN/A$0.00+∞N/AN/A$18K$102.21M0.00300High Trading VolumeVIVEViveve MedicalN/A$0.00flatN/AN/A$1K$6.83M0.0070High Trading VolumeELMDElectromed1.5027 of 5 stars$21.80-0.9%$38.00+74.3%+34.9%$182.82M$61.44M29.07160QTIQT ImagingN/A$1.33-4.1%N/A+157.9%$36.16M$4.00M0.00N/ANews CoverageGap UpNRXSNeurAxis3.4881 of 5 stars$2.38-1.7%$7.00+194.1%-9.2%$17.17M$2.93M-1.2919ENSCEnsysce Biosciences0.0827 of 5 stars$2.24+0.4%N/A-68.5%$5.31M$5.21M-0.3410ARTLArtelo Biosciences2.2907 of 5 stars$9.50-28.4%$33.00+247.4%+100.7%$5.23MN/A-0.535News CoverageAnalyst UpgradeGap UpHigh Trading VolumeAPMAptorum Group0.511 of 5 stars$0.94+2.7%N/A-77.2%$5.00M$430K0.0030Gap UpMYNZMainz Biomed3.0769 of 5 stars$1.42+0.7%$14.00+885.9%-92.4%$4.89M$890K-0.0230Gap Up Related Companies and Tools Related Companies CUTR Alternatives VRAYQ Alternatives VIVE Alternatives ELMD Alternatives QTI Alternatives NRXS Alternatives ENSC Alternatives ARTL Alternatives APM Alternatives MYNZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHFS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.